Global Chronic Idiopathic Constipation (CIC) Drugs Market Research Report 2022

Chronic idiopathic constipation (CIC) is a health condition in which a person experiences chronic symptoms of constipation, yet no visible cause can be identified through standard diagnostic testing. The term idiopathic is used because it means there is no known cause. CIC includes symptoms of difficult, infrequent, or incomplete bowel movements.
Due to the COVID-19 pandemic, the global Chronic Idiopathic Constipation (CIC) Drugs market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Chronic Idiopathic Constipation (CIC) Drugs market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Chronic Idiopathic Constipation (CIC) Drugs landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Lubiprostone accounting for % of the Chronic Idiopathic Constipation (CIC) Drugs global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospitals & Clinics segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Chronic Idiopathic Constipation (CIC) Drugs include Actavis, Chugai Pharmaceutical, Ferring International Center, Synergy Pharmaceuticals, Pfizer, GlaxoSmithKline, Roche Holding, Sanofi and Bayer, etc. In terms of revenue, the global 3 largest players have a % market share of Chronic Idiopathic Constipation (CIC) Drugs in 2021.
This report focuses on Chronic Idiopathic Constipation (CIC) Drugs volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Chronic Idiopathic Constipation (CIC) Drugs market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Chronic Idiopathic Constipation (CIC) Drugs Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Lubiprostone
Linaclotide
Others
Segment by Application
Hospitals & Clinics
Ambulatory Surgical Centres
Long Term Care Centres
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Actavis
Chugai Pharmaceutical
Ferring International Center
Synergy Pharmaceuticals
Pfizer
GlaxoSmithKline
Roche Holding
Sanofi
Bayer
Salix Pharmaceuticals
Sucampo Pharmaceuticals
Ironwood Pharmaceuticals
Progenics Pharmaceuticals

Frequently Asked Questions